Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY 77-1931 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BAY 77-1931 | DRUG | Lanthanum Carbonate (BAY 77-1931) |
Inclusion Criteria: * Undergoing hemodialysis 3 times per week for chronic renal failure for the previous 3 consecutive months at least Exclusion Criteria: * Pre-dialysis serum phosphate levels of 10.0mg/dL during the washout period
BAY 77-1931 is an investigational small molecule being developed for the treatment of hyperphosphatemia, a condition characterized by elevated phosphate levels in the blood. It is being studied in the therapeutic area of nephrology. The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
BAY 77-1931 is being developed by Bayer AG, a multinational pharmaceutical company. Bayer's stock is traded over-the-counter under the ticker symbol BAYRY. The company is conducting clinical trials to evaluate the safety and efficacy of BAY 77-1931 in patients with hyperphosphatemia.
BAY 77-1931 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies such as the FDA. The drug is being studied for the treatment of hyperphosphatemia, and its clinical development is ongoing.
BAY 77-1931 has one completed clinical trial registered under NCT00769496, titled "BAY 77-1931 Long-term Extension From Phase II Study." This Phase 2 trial enrolled 145 participants with hyperphosphatemia in Japan. The study was not randomized, double-blind, or controlled, and it included adults aged 20 years and older of all sexes.
No alternative names for BAY 77-1931 have been reported. The drug is identified solely by its code name BAY 77-1931 in clinical trial registrations and scientific literature. It is a distinct investigational compound being developed by Bayer AG for hyperphosphatemia.